
Nimocal30 mg
Square Pharmaceuticals PLC.
Nimodipine is a dihydropyridine calcium channel blocker that is FDA-approved for a single, well-defined indication in neurocritical care.
Nimodipine is a dihydropyridine calcium channel blocker that is FDA-approved for a single, well-defined indication in neurocritical care.
Nimodipine does not reverse or reduce the angiographic vasospasm itself; its clinical benefit is on neurological outcome. Treatment should be started within 96 hours of the onset of subarachnoid hemorrhage and requires a physician's supervision in a hospital setting. There is no well-established, guideline-supported role for Nimodipine outside this indication, and off-label use should only occur under direct specialist guidance.
| Population | Dose | Duration |
|---|---|---|
| Standard adult dose | 60 mg (two 30 mg capsules) orally every 4 hours | 21 consecutive days, started within 96 hours of hemorrhage onset |
| Hepatic impairment (e.g. cirrhosis) | Reduced to 30 mg orally every 4 hours, with close monitoring of blood pressure and heart rate | Same 21-day course |
Safety and efficacy in pediatric patients have not been established; Nimodipine is not used in children outside specialist/investigational settings.
The most common adverse effect of Nimodipine is a drop in blood pressure. Because subarachnoid hemorrhage itself often alters consciousness, some adverse effects may be under-reported in affected patients.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.